Search
for
Sort by
Research 30 of 823
- Keratin 6A promotes skin inflammation through JAK1-STAT3 activation in keratinocytes
- Hair growth–promoting effects of Enz_MoriL on human dermal papilla cells through modulation of the Wnt/β-Catenin and JAK-STAT signaling pathways
- JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis
- Under Development JAK Inhibitors for Dermatologic Diseases
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Scarring hair follicle destruction is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Efficacy of JAK 1/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus
- Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
- Psychological Stress-Induced Pathogenesis of Alopecia Areata: Autoimmune and Apoptotic Pathways
- 59 Scarring alopecia is driven by the collapse of EGFR-protected JAK-STAT1-sensitive stem cell immune privilege
- Dysregulation of Leukaemia Inhibitory Factor (LIF) Signalling Pathway by Supraphysiological Dose of Testosterone in Female Sprague Dawley Rats During Development of Endometrial Receptivity
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Small Molecule Inhibitors and Inflammatory Skin Diseases
- Targeting the Janus Kinase Family in Autoimmune Skin Diseases
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology
- Topical Ruxolitinib in Combination with Oral Minoxidil Results in Hair Regrowth in a Patient with Central Centrifugal Cicatricial Alopecia and Concomitant Traction Alopecia
- Alopecia universalis successfully treated with tofacitinib
- Unexpected Effect of Baricitinib Use: Observation of a Case of Hypertrichosis
- Unexpected Extensive Hair Whitening Following Baricitinib Treatment for Alopecia Universalis: A Case Report and Mechanistic Insights
- Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date
- The Sebaceous Gland - Friend or Foe?
- Good efficacy achieved by baricitinib in the treatment of anti-MDA5 antibody-positive dermatomyositis with alopecia areata
- Concomitant management of alopecia universalis and ulcerative colitis with upadacitinib
- Reversal of alopecia areata, osteoporosis follow treatment with activation of Tgr5 in mice
- Efficacy and Potential Mechanisms of Naringin in Atopic Dermatitis
- The role of janus kinases in the treatment of autoimmune skin diseases
- Upadacitinib in the treatment of a patient with the triad of atopic dermatitis, vitiligo, and alopecia areata: a case report and literature review
- The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature
- JAK-STAT1 as therapeutic target for EGFR deficiency-associated inflammation and scarring alopecia
- Successful treatment of concomitant alopecia universalis and Crohn’s disease with upadacitinib: A case report